Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magdi Elsallab

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Blood Cancer Discovery|September 27, 2021
Scalable Manufacturing of CAR T cells for Cancer ImmunotherapyMohamed Abou-El-Enein, Magdi Elsallab, Steven A Feldman, et al.
Transplantation and Cellular Therapy|December 13, 2024
Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS DataMoataz Ellithi, Magdi Elsallab, Matthew A Lunning, et al.
Blood Advances|May 17, 2023
CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell productsJonas Kath, Weijie Du, Stefania Martini, et al.
Transplantation and Cellular Therapy|May 18, 2024
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell TherapiesRebecca A Gardner, Claire White, Magdi Elsallab, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Blood Cancer Discovery|September 27, 2021
Scalable Manufacturing of CAR T cells for Cancer ImmunotherapyMohamed Abou-El-Enein, Magdi Elsallab, Steven A Feldman, et al.
Transplantation and Cellular Therapy|December 13, 2024
Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS DataMoataz Ellithi, Magdi Elsallab, Matthew A Lunning, et al.
Blood Advances|May 17, 2023
CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell productsJonas Kath, Weijie Du, Stefania Martini, et al.
Transplantation and Cellular Therapy|May 18, 2024
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell TherapiesRebecca A Gardner, Claire White, Magdi Elsallab, et al.
Pageof 2